Objective: We assessed whether surgical resection is acceptable for radiological invasive nonsmall cell lung cancer (NSCLC) that met the current high-risk criteria. Methods: We reviewed 500 clinical-Stage I NSCLCs with a radiological pure-solid appearance. Highrisk criterion was defined as follows: (1) preoperative FEV1% ≤ 50% or DLco% ≤ 50%, (2) age > 75y with 50% < FEV1% < 60% or 50% < DLco% < 60%, and (3) three or more severe general comorbidities. Results: The high-risk group comprised 184 (37%) patients. The percentages for elderly, male, smoker, non-adenocarcinoma histology were significantly higher than those of the normal-risk group (P < 0.001). Lobectomy was performed in 148 (80%) patients. Overall survival (OS) was significantly worse in the high-risk group (59.4% vs 73.1%, P = 0.004), however, a multivariate analysis revealed that high-risk was not associated with poor survival (P = 0.519). Furthermore, there were no significant differences between the high-risk and normal-risk groups regarding cancer-specific survival (74.5% vs 79.2%, P = 0.569). Postoperative morbidity rates were significantly different between the two study arms (45% vs 25%, P < 0.001), however, the 30-day and 90-day mortality rates for the high-risk group were 1.6% and 3.8%, respectively. In the high-risk patients, the difference in survival between lobectomy and sublobar resection was not significant (69.4% vs 78.6%, P = 0.716), and was also proven in the propensity-score matched patients (82.1% vs 76.0%, P = 0.623). Conclusions: Conventional high-risk criteria are not always appropriate prognostic variables, and lung cancer specific survival or short-term mortalities for high-risk patients were fully acceptable. Surgical therapy including lobectomy should not be readily excluded from radical local management even when a patient meets the high-risk criteria.
Introduction
Pulmonary lobectomy with systematic lymph node dissection or sampling is a standard surgical procedure in operable clinical-Stage I non-small cell lung cancer (NSCLC) (1, 2) . Evidence supporting this practice is derived from a randomized prospective trial comparing lobectomy with sublobar resections conducted by a Lung Cancer Study Group (LCSG) (3) , which found a significantly higher recurrence rate and a trend toward poor survival for the latter. In an increasingly aging population where pulmonary insufficiencies and cardiac complications are prevalent, lung cancer patients who are considered unsuitable for lobectomy could be optimal candidates for sublobar resection. Moreover, the results of limited surgery for compromised patients could be acceptable (4, 5) . In addition, current prospective clinical trials have investigated the efficacy of nonsurgical treatment including stereotactic body radiotherapy (SBRT) and radiofrequency ablation (RFA) for early-stage NSCLC patients considered as medically inoperable or high-risk for surgical intervention (6, 7) . However, are the criteria that have used in several prospective trials really considered as 'high-risk' in our daily practice? A clear rationale for the criteria used to determine whether or not a patient is medically high-risk has yet to be reached (4, 8, 9) . Furthermore, the oncological outcome of SBRT remains dismal for patients with radiological pure-solid appearances compared with those having pure ground glass opacity (GGO) or part-solid lesions, possibly on account of the poor locoregional control against such highly invasive tumors (10) . Therefore, it is extremely hazardous to use the current high-risk criteria to include non-surgical treatment for NSCLCs and to interpret study results without deliberate consideration, when definition of high-risk seems to be obscure.
From the oncological point of view, it goes without saying that surgical resection including major lung resection is truly needed as a definitive local treatment therapy especially for radiological pure-solid, Categorical data are shown as numbers (%) and continuous data as mean ± SD if normally distributed, and median ± IQR if not normally distributed (range), NSCLC, non-small cell lung cancer; VC, vital capacity; FEV1, forced expiratory volume in 1 second; DLco, carbon monoxide pulmonary diffusing capacity; CEA, carcinoembryonic antigen; lob, lobectomy; seg, segmentectomy; HOT, home oxygen therapy; IP, intestinal pneumonia. *P value in Chi square test, Student's t-test or Wilcoxon rank sum test.
i.e. invasive NSCLC (11) (12) (13) . In contrast, we have often encountered a challenging clinical scenario where medically compromised patients present with a tumor that has a radiological invasive appearance requiring radical surgery for a complete resection. Thus, in the present study, we aimed to explore whether the prevailed high-risk criteria is appropriate for use in our practice, and whether surgical therapy is acceptable as a treatment strategy, in terms of oncological outcome, for clinical-Stage I radiological pure-solid, i.e. more aggressive NSCLC patients who meet the high-risk criteria based on current clinical trials.
Materials and methods

Study population
Between 2008 and 2013, we retrospectively evaluated 500 surgically resected clinical-Stage I radiological pure-solid NSCLCs on thin-section CT scan. Any clinical-Stage I lung adenocarcinoma with a GGO component was excluded from the study. The database has been maintained prospectively, and so there was no missing data for the variables in this study. The inclusion criteria were preoperative staging determined by thin-section CT or F-18-fluorodeoxyglucose positron emission tomography (FDG-PET) scans, and complete resection without preoperative chemo-and/or radiotherapy. With regard to the clinical nodal assessment, clinical-N0 meant non-enlarged lymph nodes on CT scan and negative FDG uptake by the lymph nodes. Invasive modalities for mediastinal lymph node staging, such as mediastinoscopy or endobronchial ultrasound-guided transbronchial needle aspiration were not routinely used preoperatively because they were evaluated by thin-section CT or FDG-PET/CT. The study protocol was approved by the institutional review boards of Juntendo University School of Medicine (IRB No. 13-176). As this was a retrospective study, the need to obtain written informed consent from each patient was waived. Categorical data are shown as numbers (%) and continuous data as mean ± SD if normally distributed, and median ± IQR if not normally distributed (range). *P value in Chi square test, Student's t-test or Wilcoxon rank sum test
Criteria of high risk patients
Based on the clinical trials where the high-risk criteria were used, namely, SBRT or limited resection for NSCLC (7, 14, 15) , the highrisk patients in the current study were essentially defined as follows:
(1) preoperative FEV1%≤50% or DLco%≤50%, (2) age > 75y with 50% < FEV1% < 60% or 50% < DLco% < 60%. In addition to these conventional high-risk criteria, the following was also included to modify the current high-risk criteria (7); (3) patients with three or more severe comorbidities including severe chronic heart disease, chronic cerebral, cardiac, or peripheral vascular disease and diabetes mellitus with severe end organ disease.
Radiological evaluations on thin-section CT scan
For all patients, findings of the preoperative thin-section CT scan were reviewed in detail by the authors (A.H., T.M. and K.S.). Tumor size was determined preoperatively based on thin-section CT scan with 2 mm collimation. The lung was photographed with a window level of −500 to −700 H and a window depth of 1000-2000 H as the 'lung window', and a window level of 30-60 H and a window depth of 350-600 H as the 'mediastinal window'. Consolidation tumor ratio (CTR) was defined as the ratio of the maximum size of consolidation to the maximum tumor size on thin-section CT scan (16) . In this study, a radiological pure-solid tumor was defined as a lung tumor showing only consolidation without GGO on thin-section CT, i.e. CTR was equal to 1.0 (11-13).
Operation policy
Lobectomy with systematic or selective lymph node dissection is a standard surgical policy in our institute for radiologically pure-solid tumors due to their high malignant potential. However, segmentectomy or wedge resection is occasionally indicated for some patients who are not lobectomy tolerable such as the very elderly and cardiopulmonary high risk patients, even when tumors show a radiological pure-solid appearance. Values for overall survival (OS) and cancer-specific survival (CSS) were calculated by Kaplan-Meier estimation methods using logrank test. The date of surgical resection was set as the starting point, and the date of any cause or lung cancer related death or last date of follow-up as the end point. Reported continuous data were shown as means and standard deviation (SD) for normality. Furthermore, propensity-score matching was applied to balance the assignments of the eligible patients. Clinical variables including age, gender, maximum tumor size, carcinoembryonic antigen (CEA, ng/ml), pulmonary functions, smoking status and clinical-stage were multiplied by a coefficient that was calculated from a logistic regression analysis, and the sum of these values was taken as the propensity score for each patient. In the high-risk group, patients that underwent lobectomy or sublobar resection with equivalent propensity scores were selected by a 1 to 1 match to clarify the real survival difference among the two subgroups. Statistical analysis was considered significant when the probability value was less than 0.05.
Results
Overall characteristics of the surgically resected clinical-Stage I radiological pure-solid NSCLC patients are presented in Table 1 . Of these patients, 184 (37%) were classed in the high-risk group, while 316 (63%) in the normal-risk group. Preoperative histological diagnosis was confirmed in 156 (31%) patients, while the remaining patients were proven by intraoperative frozen section diagnosis. The proportion of elderly patients, males, smokers and non-adenocarcinoma histology were higher in the high-risk group than the normal-risk group (P < 0.001). Although significant differences were observed in the operative procedures between the two study groups, the percentage of patients who underwent lobectomy and mediastinal nodal dissection were 148 (80%) and 129 (70%), respectively, even in the high-risk group. With regard to the perioperative surgical outcomes, overall perioperative morbidity rate was significantly higher in the high-risk group than the normal-risk group (45% vs 25%, P < 0.001), and most cases were due to respiratory related complications. Subsequently, frequency of death due to reasons other than lung cancer was significantly higher in the high-risk group (12% vs 4%, P = 0.002), however, the 30-day and 90-day mortality rates of the highrisk group were 1.6% and 3.8%, respectively. Table 2 shows the perioperative surgical outcomes of 427 patients that underwent lobectomy. Overall perioperative morbidity rate was also significantly higher in the high-risk group than the normal-risk group (50% vs 25%, P < 0.001), however, the 30-day and 90-day mortality rates were 2.0% and 4.0%, respectively.
With regard to OS of the surgically resected clinical-Stage I radiological pure-solid NSCLC patients, 3y-OS was 79.5% and 5y-OS was 68.7%, with a mean follow-up time of 42 months. Figure 1 shows the Kaplan-Meier curves of the high-risk and normal-risk groups. OS was significantly different between the two study groups for patients with clinical-Stage I radiological pure-solid NSCLC ( Fig. 1A; 59 .4% vs 73.1%, P = 0.004), and for those who underwent lobectomy (Fig. 1B; 56 .8% vs 74.6%, P = 0.007). However, as shown in Table 3 , Cox proportional hazard model revealed that age, sex, maximum tumor size, CEA and pathological-stage, and the extent of nodal dissection were independently significant prognostic factors of survival (P = 0.022, 0.023, 0.022, 0.049, <0.001, 0.001, respectively), while a multivariate analysis revealed that high-risk was not associated with poor survival (P = 0.519). Therefore, we evaluated the CSS between the high-risk and normal-risk groups. There was no significant difference between the groups regarding 5y-CSS in patients with clinical-Stage I pure-solid NSCLC ( Fig. 2A; 74.5% vs 79.2%, P = 0.569), and the same was true for patient who underwent lobectomy ( Fig. 2B; 72 .7% vs 81.5%, P = 0.481).
Furthermore, we compared the difference in survival between lobectomy and sublobar resection in the high-risk group. Significant differences were observed for several clinicopathological variables, however, perioperative surgical outcomes were almost equivalent between the two study groups (Table 4) . With regard to the 5y-OS, significant difference between the lobectomy and sublobar resection groups was not observed in the high-risk patients (Fig. 3A; 69.4% vs 78.6%, P = 0.716). Moreover, we compared patient characteristics among the high-risk patients using a propensity-score matched analysis for elucidating the prognostic impact based on surgical mode (Table 5) . After matching the clinical covariates, OS was not significantly different between the lobectomy and sublobar resection groups in the propensity-score matched pairs ( Fig. 3B; 82 .1% vs 76.0%, P = 0.623).
Comment
This study demonstrated that the current high-risk criteria often used in several clinical trials are not always appropriate prognostic variables as revealed by the multivariate analyses. Although the incidence of postoperative morbidities was greater and OS was significantly poor among the high-risk patients compared to the normal-risk 11.1 ± 6.1 (4-49) 9.6 ± 4.9 (4-25) 0.198
Categorical data are shown as numbers (%) and continuous data as mean ± SD if normally distributed, and median ± IQR if not normally distributed (range). *P value in Chi square test, Student's t-test or Wilcoxon rank sum test.
patients, CSS was almost equivalent between the two study arms. With regard to the 30-day or 90-day mortalities, significant differences were observed between the two study arms. However, the respective values of the high-risk patients were 1.6% and 3.8%. The statistical differences might be attributable to the prominent surgical results of the normal-risk group in our surgical series (30-day mortality was 0%, and 90-day mortality was 0-0.3%). Furthermore, the short-term surgical results of the high-risk group were fully comparable to previous data (30-day mortality; 1.4-3.7%, 90-day mortality; 3.9-6.9%) (6, 8, 9, 18, 19) , taking the high frequency of high-risk patients who underwent lobectomy in our surgical series into consideration. Therefore, our result does not support use of the current high-risk criteria as a means of excluding patients from definitive surgical resection or to include them in studies of non-surgical treatments such as SBRT or RFA.
With regard to an appropriate treatment strategy for patients with clinical-Stage I NSCLC, pulmonary lobectomy with systematic lymph node dissection or sampling is the gold standard therapy for resectable NSCLC (3) . Recently, those findings are being challenged by several observation studies that demonstrate long-term outcomes following segmentectomy to be equivalent to those following lobectomy especially for selected tumors showing a part-solid, i.e. GGO appearance. Such tumors correspond well to histologically indolent or less invasive lung adenocarcinomas (20) , and their oncological outcomes are excellent (11) . This indicates that limited surgical resection could be radical for GGO dominant tumors even when such patients show a physically compromised state. Oncologically, however, NSCLCs showing a radiologically pure-solid appearance without any GGO component are considered to be highly invasive compared with those of a part-solid tumor. Postoperative nodal involvement is found in~15-20% of patients with radiological pure-solid NSCLC even in early or small lesions (11) (12) (13) . For such patients, lobectomy remains the mainstay surgical mode from the point of radical locoregional management (21, 22) .
In contrast, the treatment strategy for patients defined as high-risk is really controversial especially when the tumor shows a solid appearance. Acceptable oncologic outcomes of SBRT or RFA have been reported for medically inoperable NSCLCs (6,7), however, local control and long-term survival of SBRT are dismal for radiological pure-solid NSCLCs (10) . Pulmonary function could be the major criterion for indicating limited surgery for patients in a physically compromised state. However, we must take several oncological aspects into consideration, such as tumor size, CTR, tumor location or surgical margin to prevent locoregional failure as much as possible. This policy should be particularly applied in cases of radiological puresolid NSCLCs due to their possible aggressive pathological behaviors.
Furthermore, the high-risk group potentially includes patients who are elderly, male and smokers (4, 23) , and have also been included in this study. High-risk patients undergoing lobectomy are more likely to experience peri-or postoperative complications, and at the same time, maybe at a lower risk of lung cancer death as a result of comorbidities (24, 25) . In the current study, 80% of the patients with clinical-Stage I radiological pure-solid NSCLC underwent lobectomy for the complete surgical resection despite their high-risk status. However, perioperative surgical outcomes and prognosis in the current study were not significantly different between the lobectomy and sublobar resection patients in the highrisk group, which was also proven in the propensity score matched pairs. Generally, strict patient selection and meticulous perioperative management are mandatory for patients who meet the high-risk criteria, however, our results strongly support the finding that radical surgical intervention would be feasible for some patients with a radiological pure-solid tumor even when they are physically compromised. When selecting the appropriate operative mode for patients that meet the current high-risk criteria, general activity in daily life is much more important than values resulting from several examinations when the balance between expected long-term oncological outcomes and perioperative surgical morbidity is considered.
This study is limited by its retrospective nature, and being a single center experience. Another limitation would be a relatively short follow-up period. Furthermore, comparison of the outcomes between surgery and non-surgical therapy such as SBRT and RFA is needed to evaluate which strategy is more feasible for medically high risk patients, although it is often difficult to recruit patients for such a clinical trial. Hence, further investigations are warranted in the future. Despite these limitations, however, our results are based on the large Figure 3 . Significant difference was not observed between the lobectomy and sublobar resection groups among the high-risk patients (A: 69.4% vs 78.6%, P = 0.716), and the same was true for the propensity-score matched patients (B: 2.1% vs 76.0%, P = 0.623).
data set gathered to date, and the cohort was limited exclusively to radiological pure-solid NSCLCs, which are considered to be more aggressive. Moreover, definitive treatment is truly mandatory for strict local management. To obtain a real consensus regarding high risk criteria, a multi-disciplinary meeting is needed to lead to some consensus.
In conclusion, the present study suggested that the criteria for a high-risk surgical candidate that were used in the SBRT or RFA trial may not be ideal as some patients who underwent non-surgical treatment for NSCLC could fully tolerate a definitive surgical resection including lobectomy. Our results indicate that the selection criteria for medically high-risk patients should be reevaluated for use in daily practice. Opportunities for definitive surgical management including lobectomy should not be easily precluded in cases of clinical-Stage I NSCLC, particularly those showing a radiological pure-solid appearance. 
